Fleroxacin

06/01/1986 - "The excellent therapeutic efficacy of AM-833 against these systemic and local infections may be a result of its good oral absorption and high levels in tissues."
03/22/1993 - "Concentrations of fleroxacin in human body fluids and tissues were studied to obtain information about the efficacy of the drug at the site of infection and the ratio of fleroxacin concentrations in tissue or fluid versus those in plasma as a measure of the extent of penetration. "
03/22/1993 - "Efficacy of oral fleroxacin in bone and joint infections."
03/22/1993 - "A total of 20 (91%) of the fleroxacin-treated patients and 29 (88%) of the AMX/CP-treated patients were bacteriologically cured (two fleroxacin- and one AMX/CP-treated patients developed super-infection). "
05/01/1995 - "Fleroxacin 400mg once daily also achieved bacteriological cure in approximately 80% of patients with bone and joint infections in preliminary studies. "

07/01/1998 - "Therefore, it may be expected that half of the dose of fleroxacin gives comparable results in the treatment of urinary tract infections; this should be substantiated in comparative clinical trials."
09/01/1995 - "A sequential study of intravenous and oral Fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections."
10/01/1993 - "In comparison of participant and reference laboratory zone diameters, absolute qualitative agreement was 88.7% for the approved NCCLS interpretive criteria and 94.8% for the criteria used in the fleroxacin urinary tract infection clinical trials. "
03/22/1993 - "A sequential study of intravenous and oral fleroxacin in the treatment of complicated urinary tract infection."
10/01/1997 - "Lower doses of fleroxacin (200 mg. once daily) should only be used to treat urinary tract infections caused by gram-negative organisms with minimum inhibiting concentrations of less than 0.5 mg./l."

05/01/1992 - "Fleroxacin, as a single oral dose, is an effective treatment for culture-proven chancroid in patients who are HIV-1 seronegative. "
05/01/1989 - "We performed an initial randomized clinical trial to assess the efficacy of fleroxacin for treatment of chancroid in Nairobi, Kenya. "
03/22/1993 - "Fleroxacin was prescribed to treat both HIV-negative and HIV-positive men with proven chancroid in an open study. "
03/22/1993 - "Fleroxacin in the treatment of chancroid: an open study in men seropositive or seronegative for the human immunodeficiency virus type 1."
03/22/1993 - "Fleroxacin is an acceptable alternative to existing treatment regimens for chancroid in men."

03/22/1993 - "This study was designed to test the efficacy of 400 mg fleroxacin given orally as a single dose or once daily for 3 days against acute bacterial diarrhea. "
03/22/1993 - "Treatment of acute bacterial diarrhea: a multicenter international trial comparing placebo with fleroxacin given as a single dose or once daily for 3 days."
03/22/1993 - "In The Gambia, 195 tourists with acute diarrhea were randomized in a double-blind, controlled trial into three treatment groups: fleroxacin 400 mg for 1 day, fleroxacin 400 mg daily for 2 days, and placebo. "
01/01/1997 - "[Single dose of fleroxacin for the treatment of adult acute diarrhea]."
03/22/1993 - "A single dose of fleroxacin 400 mg may be recommended for the self-treatment of travelers' diarrhea."

10/01/1996 - "In the open and randomized trials, fleroxacin cured eighty cases of bacterial infections, the overall clinical efficacy rate was 90.0%, the culturing rate in the flero-xacin group was 83.8%, the bacterial clearance rate was 88.2% and the incidence of adverse reactions was 9.6%. "
10/01/1996 - "A randomized controlled study was carried out to treat sixty patients with urinary tract and respiratory tract bacterial infections, thirty in each group with one of the two drugs, and fifty cases were treated with fleroxacin in an open trial. "
10/01/1996 - "[A clinical study in the treatment of acute bacterial infections with fleroxacin]."
03/22/1993 - "Fleroxacin may be indicated for the treatment of acute bacterial infection in chronic bronchitis known to be due to Haemophilus species and Moraxella catarrhalis. "
06/01/1986 - "The protective effects of a single oral dose of AM-833 on systemic bacterial infections in mice were greater than those of norfloxacin. "